新浦京8883net游戏(中國)官方網站Pro-One

Chronicle of events

Chronicle of events

2023

In February 2023Liujiang Pharmaceutical, a subsidiary of Zhien Biotechnology, was recognized by the Chongqing Enterprise Technology Research and Development Center

In May 2023Zhien Biologics Olistat Capsules became the first in China to pass the national drug quality and efficacy consistency evaluation

In May 2023the Jinfeng Branch of Zhien Biotechnology successfully passed the on-site inspection of GMP compliance for the entrusted production of donepezil hydrochloride tablets and ropinib hydrochloride tablets

In June 2023Lanjiang Pharmaceutical Co., Ltd., a subsidiary of Zhi'en Biotechnology, was approved for marketing with its oral solution of Tomoxetine hydrochloride

In June 2023Zhi'en Biotechnology and Danahe's subsidiary, Graysay Life Technology (Shanghai) Co., Ltd. (Cytova), signed the "Situofan Western Science and Technology Innovation Center Co construction Agreement"

In March 2023Ruien Pharmaceutical, a subsidiary of Zhien Biotechnology, was recognized as a "Chongqing Science and Technology Enterprise"

In June 2023Liujiang Pharmaceutical, a subsidiary of Zhi'en Biotechnology, was recognized as a "specialized, refined, unique, and new small and medium-sized enterprise" in Chongqing

In June 2023subsidiaries of Zhien Biotechnology, Liujiang Pharmaceutical and Ruien Pharmaceutical, were recognized as "innovative small and medium-sized enterprises"

In July 2023Zhien Biotechnology and Junshi Biotechnology (1877. HK, 688180. SH) signed a cooperation agreement

In July 2023Zhi'en Biotech's raw materials of flupentixol hydrochloride, rivaroxaban, and terbutaline sulfate were approved for marketing

In August 2023 Zhien Biotechnology Jinfeng Branch successfully passed the entrusted production license inspection and on-site GMP compliance inspection for Metsulfolast granules of the drug

In September 2023Xingchuang Pharmaceutical, a subsidiary of Zhien Biotechnology, successfully obtained the B certificate of the Drug Production License and became the holder of the Drug Marketing License (MAH)

In September 2023Zhi'en Biotechnology signed a cooperation agreement with the Chongqing High tech Industrial Development Zone Management Committee, Maiwei (Shanghai) Biotechnology Co., Ltd. (688062. SH), and Chongqing Zhongxin Pharmaceutical Health Private Equity Investment Fund Partnership Enterprise

In September 2023Zhien Biotechnology Jinfeng Branch successfully passed the on-site registration verification of Omeprazole Magnesium Bicarbonate Sodium Capsules (Class 2 Innovative Drugs) and the GMP compliance inspection of entrusted production

In September 2023Zhi'en Biologics approved the marketing of rivaroxaban tablets

In September 2023Lanjiang Pharmaceutical's Lacosamide Oral Solution, a subsidiary of Zhi'en Biotechnology, was approved for marketing

In September 2023Zhi'en Biotechnology won the "Chongqing Enterprise Innovation Award"

In October 2023Zhi'en Biotechnology was ranked among the top 100 private manufacturing enterprises in Chongqing and the top 100 technology innovation index for private enterprises in Chongqing in 2023

In November 2023the subsidiary of Zhi'en Biotechnology, Lanjiang Pharmaceutical, selected the ninth batch of national drug centralized procurement from the oral solution of Lakoxamide and the oral solution of Tomoxetine hydrochloride

In November 2023the production lines of Levaroxaban, Terbutaline Sulfate, and Flupenthiazide Hydrochloride of Zhien Biological Dinglian Branch successfully passed the on-site GMP compliance inspection

In November 2023Zhien Biotechnology and Danaher signed a cooperation agreement

In December 2023Zhi'en Biotechnology and Yusong Pharmaceutical signed a strategic cooperation agreement

In December 2023Zhi'en Biological Hydrochloride Memantine API was approved for marketing

In December 2023Zhi'en Biotechnology successfully passed the national "high-tech enterprise" review

In December 2023subsidiary companies of Zhien Biotechnology, Liujiang Pharmaceutical and Lanjiang Pharmaceutical, successfully passed the national "high-tech enterprise" certification

In December 2023Zhi'en Biotechnology was successfully selected as the Excellent Engineer Practice Base in Chongqing City

2023

2022

In January 2022Rated as National Enterprise Technology Center

In January 2022the first and exclusive evaluation of the consistency of generic drug quality and efficacy was conducted in China for "Ropinilo Hydrochloride Tablets (0.5mg and 3mg)"

In January 2022 the first biopharmaceutical "BZ1001 project" of Zhi'en Biotechnology obtained a drug clinical trial license

In March 2022"Tadalafil Tablets (20mg)" won the drug registration certificate.

In March 2022the "Abercept Intraocular Injection Solution" officially obtained clinical implied permission

In May 2022the supplementary application for the process change of "tropisetron hydrochloride" API was approved by the National Medical Products Administration

In May 2022the Zhi'en Biopharmaceutical Conversion Center was completed and the biopharmaceutical project was officially put into operation

In May 2022the Cell Preparation Center of Zhi'en Translational Medicine Research Institute was officially put into operation

In June 2022,the construction of the factory building and supporting facilities for the Zhi'en Modern Traditional Chinese Medicine Project (Phase I) officially began

In June 2022 Orlistat (T12) production digital workshop was identified as Chongqing digital workshop in 2022

In June 2022Successfully docked with the top node of national identity analysis, and launched the construction of the characteristic industrial internet in the plant based biopharmaceutical industry

In July 2022 the subsidiary Chongqing Enchuang Medical Management Co., Ltd. was awarded the "Drug Production License"

In August 2022A joint venture agreement was officially signed with Baifan Biotechnology, and Feifan (Chongqing) Biopharmaceutical Co., Ltd. was officially registered

In September 2022 "Metformin Hydrochloride" was approved for commercial production

in September 2022Recognized as the fourth batch of national specialized, refined, and new "little giant" enterprises

in September 2022The Western Science City Biopharmaceutical High end Manufacturing Base Project was launched

In November 2022A strategic cooperation agreement was signed with Situofan to build a "life core valley" in the central and western regions

In November 2022Changshou A02 Workshop Orlistat production line officially passed the GMP compliance inspection

in November 2022Recognized as a national intellectual property demonstration enterprise

In November 2022Rated as one of the top 100 private manufacturing enterprises in Chongqing

2022

2021

In January 2021Cooperation framework agreements and memorandums of understanding were signed with China Resources 39 Company and Grayssey Life Technology Company respectively

In January 2021Its subsidiary "Haizheng Xuantai" was approved for the first MAH "Drug Production License"

In February 2021 Dinglian Branch was awarded the titles of "Advanced Collective for Safety Production in Changshou Economic and Technological Development Zone", "Advanced Collective for Environmental Protection Production in Changshou Economic and Technological Development Zone", and "Excellent Contracting Unit for Standardized Construction of Contractor Safety" in 2020

IN February 2021 Lingsu ® Quetiapine fumarate sustained-release tablets won the bid successfully in the fourth batch of national centralized procurement

In April 2021The "Grateful Peer · Innovative Sailing -20th Anniversary Celebration and Key Project Press Conference of Plant En Biology" was held

In August 2021Received the honorary title of "Selected Cases of Top 10 Smart Health Applications in Chongqing in 2021"

In November 2021The Orlistat project team won the the State Technological Innovation Award

In December 2021Construction of the Biopharmaceutical R&D and Industrialization Research Center commenced

2021

2019~2020

In February 2019“donepezil hydrochloride tablets” was the first to pass the consistency evaluation

In July 2019our “orlistat”, “orlistat capsules” and “donepezil hydrochloride tablets” were awarded as the 2018 major new products in Chongqing

In January 2020“donepezil hydrochloride tablets” (5mg) won the bid for the second national centralized procurement

In June 2020we were awarded the approval number of “donepezil hydrochloride tablets (10mg)”

In December 2020we were renamed as “Zein Biotechnology Co., Ltd.”

2019~2020

2014~2017

In September 2014we were awarded as a national high-tech enterprise.

In October 2014"orlistat" was awarded as a national key new product

In November 2014we were awarded as an enterprise technology center in Chongqing

In December 2017we established Jinfeng Branch of Chongqing Zein Pharmaceutical Co., Ltd.

2014~2017

2013

In January 2013we consolidated and merged Chongqing Reben Drug R&D Co., Ltd.

In May 2013we were the first enterprise that obtained the approval number of “ropinirole hydrochloride tablets”.

In October 2013we were awarded as a national and local joint engineering research center

In October 2013we were awarded as an engineering technology research center of Chongqing new drug design enterprise

In December 2013“ropinirole hydrochloride tablets” was awarded as one of the “2013 top ten great prescription drugs in China”

2013

2012

In August 2012we consolidated and merged Chongqing Dinglian Pharma Co., Ltd.

In October 2012we were awarded as a key high-tech enterprise of the National Torch Program

In December 2012we established Dinglian Branch of Chongqing Zein Pharmaceutical Co., Ltd.

In November 2012we obtained the approval number of “suplatast tosilate” exclusively

2012

2011

In July 2011we were approved to set up a postdoctoral research workstation in Chongqing

In November 2011we were awarded as a new drug design engineering technology research center in Chongqing

In December 2011we were awarded as Chongqing chiral drugs enterprise engineering technology research center

In December 2011we were awarded as Chongqing chiral drugs engineering technology research center

In December 2011we were awarded as an engineering research center for innovative drugs and advanced drugs manufacturing technology

2011

2001~2010

In April 2001Chongqing Zein Pharmaceutical Co., Ltd. was established

In July 2002we obtained the approval number of “Donepezil Hydrochloride Tablets” 5mg specification

In September 2003 we marketed the generic drug “Tropisetron Hydrochloride Injection”

In November 2005we established Chongqing Dinglian Pharma Co., Ltd.

In March 2010we consolidated and merged Chongqing Sangtian Pharma Co., Ltd.

In April 2010we were the first enterprise to obtain the approval number of orlistat

2001~2010

Fax:

微信公众号